|
Dec 7
|
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
|
|
Dec 5
|
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
|
|
Dec 1
|
New Strong Buy Stocks for December 1st
|
|
Nov 29
|
Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?
|
|
Nov 28
|
Best Momentum Stocks to Buy for November 28th
|
|
Nov 28
|
New Strong Buy Stocks for November 28th
|
|
Nov 27
|
Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know
|
|
Nov 27
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
|
|
Nov 16
|
Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know
|
|
Nov 10
|
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
|
|
Nov 10
|
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
|
|
Nov 8
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript
|
|
Nov 6
|
Aquestive Therapeutics Inc (AQST) Reports 25% Year-Over-Year Growth in Year-to-Date Revenue
|
|
Nov 6
|
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 2
|
Aquestive Therapeutics Completes $45 Million Debt Refinancing
|
|
Nov 1
|
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Oct 31
|
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
|
|
Aug 11
|
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 11% loss last week hit both individual investors who own 60% as well as institutions
|
|
Aug 10
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Call Transcript
|
|
Aug 7
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
|